New therapies for prostate cancer?
Tanowitz
Herbert B
HB
Departments of Pathology and Medicine, Albert Einstein College and Medicine, Bronx, New York, USA. herbert.tanowitz@einstein.yu.edu
Machado
Fabiana S
FS
D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects*; D018797:Cell Cycle Proteins / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects*; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors; D003619:Dansyl Compounds / Q000494:pharmacology*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism
D000225:Adenine; D000970:Antineoplastic Agents; D018797:Cell Cycle Proteins; D018844:Cyclin-Dependent Kinases; D003619:Dansyl Compounds; D018719:Erb-b2 Receptor Tyrosine Kinases; C557984:2-chloro-N-(2-(5-(dimethylamino)naphthalene-1-sulfonamido)ethyl)-4-(2-(1-hydroxy-3-methylbutan-2-ylamino)-9-isopropyl-9H-purin-6-ylamino)benzamide